Cargando…
2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma
Adoptive cellular immunotherapy with chimeric antigen receptor (CAR) T cells has emerged as a novel modality for treating relapsed and/or refractory B-cell non-Hodgkin lymphoma (B-NHL). With increasing approval of CAR T-cell products and advances in CAR T cell therapy, CAR T cells are expected to be...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Compuscript
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978889/ https://www.ncbi.nlm.nih.gov/pubmed/36861439 http://dx.doi.org/10.20892/j.issn.2095-3941.2022.0585 |
_version_ | 1784899619584475136 |
---|---|
author | Li, Ping Liu, Yang Liang, Yun Bo, Jian Gao, Sujun Hu, Yongxian Hu, Yu Huang, He Huang, Xiaojun Jing, Hongmei Ke, Xiaoyan Li, Jianyong Li, Yuhua Liu, Qifa Lu, Peihua Mei, Heng Niu, Ting Song, Yongping Song, Yuqin Su, Liping Tu, Sanfang Wang, Jianxiang Wu, Depei Wang, Zhao Xu, Kailin Ying, Zhitao Yang, Qingming Zhang, Yajing Shi, Fengxia Zhang, Bin Zhang, Huilai Zhang, Xi Zhao, Mingfeng Zhao, Weili Zhao, Xiangyu Huang, Liang Zhu, Jun Qian, Wenbin Han, Weidong Liang, Aibin |
author_facet | Li, Ping Liu, Yang Liang, Yun Bo, Jian Gao, Sujun Hu, Yongxian Hu, Yu Huang, He Huang, Xiaojun Jing, Hongmei Ke, Xiaoyan Li, Jianyong Li, Yuhua Liu, Qifa Lu, Peihua Mei, Heng Niu, Ting Song, Yongping Song, Yuqin Su, Liping Tu, Sanfang Wang, Jianxiang Wu, Depei Wang, Zhao Xu, Kailin Ying, Zhitao Yang, Qingming Zhang, Yajing Shi, Fengxia Zhang, Bin Zhang, Huilai Zhang, Xi Zhao, Mingfeng Zhao, Weili Zhao, Xiangyu Huang, Liang Zhu, Jun Qian, Wenbin Han, Weidong Liang, Aibin |
author_sort | Li, Ping |
collection | PubMed |
description | Adoptive cellular immunotherapy with chimeric antigen receptor (CAR) T cells has emerged as a novel modality for treating relapsed and/or refractory B-cell non-Hodgkin lymphoma (B-NHL). With increasing approval of CAR T-cell products and advances in CAR T cell therapy, CAR T cells are expected to be used in a growing number of cases. However, CAR T-cell-associated toxicities can be severe or even fatal, thus compromising the survival benefit from this therapy. Standardizing and studying the clinical management of these toxicities are imperative. In contrast to other hematological malignancies, such as acute lymphoblastic leukemia and multiple myeloma, anti-CD19 CAR T-cell-associated toxicities in B-NHL have several distinctive features, most notably local cytokine-release syndrome (CRS). However, previously published guidelines have provided few specific recommendations for the grading and management of toxicities associated with CAR T-cell treatment for B-NHL. Consequently, we developed this consensus for the prevention, recognition, and management of these toxicities, on the basis of published literature regarding the management of anti-CD19 CAR T-cell-associated toxicities and the clinical experience of multiple Chinese institutions. This consensus refines a grading system and classification of CRS in B-NHL and corresponding measures for CRS management, and delineates comprehensive principles and exploratory recommendations for managing anti-CD19 CAR T-cell-associated toxicities in addition to CRS. |
format | Online Article Text |
id | pubmed-9978889 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Compuscript |
record_format | MEDLINE/PubMed |
spelling | pubmed-99788892023-03-03 2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma Li, Ping Liu, Yang Liang, Yun Bo, Jian Gao, Sujun Hu, Yongxian Hu, Yu Huang, He Huang, Xiaojun Jing, Hongmei Ke, Xiaoyan Li, Jianyong Li, Yuhua Liu, Qifa Lu, Peihua Mei, Heng Niu, Ting Song, Yongping Song, Yuqin Su, Liping Tu, Sanfang Wang, Jianxiang Wu, Depei Wang, Zhao Xu, Kailin Ying, Zhitao Yang, Qingming Zhang, Yajing Shi, Fengxia Zhang, Bin Zhang, Huilai Zhang, Xi Zhao, Mingfeng Zhao, Weili Zhao, Xiangyu Huang, Liang Zhu, Jun Qian, Wenbin Han, Weidong Liang, Aibin Cancer Biol Med Consensus Adoptive cellular immunotherapy with chimeric antigen receptor (CAR) T cells has emerged as a novel modality for treating relapsed and/or refractory B-cell non-Hodgkin lymphoma (B-NHL). With increasing approval of CAR T-cell products and advances in CAR T cell therapy, CAR T cells are expected to be used in a growing number of cases. However, CAR T-cell-associated toxicities can be severe or even fatal, thus compromising the survival benefit from this therapy. Standardizing and studying the clinical management of these toxicities are imperative. In contrast to other hematological malignancies, such as acute lymphoblastic leukemia and multiple myeloma, anti-CD19 CAR T-cell-associated toxicities in B-NHL have several distinctive features, most notably local cytokine-release syndrome (CRS). However, previously published guidelines have provided few specific recommendations for the grading and management of toxicities associated with CAR T-cell treatment for B-NHL. Consequently, we developed this consensus for the prevention, recognition, and management of these toxicities, on the basis of published literature regarding the management of anti-CD19 CAR T-cell-associated toxicities and the clinical experience of multiple Chinese institutions. This consensus refines a grading system and classification of CRS in B-NHL and corresponding measures for CRS management, and delineates comprehensive principles and exploratory recommendations for managing anti-CD19 CAR T-cell-associated toxicities in addition to CRS. Compuscript 2023-02-15 2023-03-02 /pmc/articles/PMC9978889/ /pubmed/36861439 http://dx.doi.org/10.20892/j.issn.2095-3941.2022.0585 Text en Copyright: © 2023, Cancer Biology & Medicine https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY) 4.0 (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Consensus Li, Ping Liu, Yang Liang, Yun Bo, Jian Gao, Sujun Hu, Yongxian Hu, Yu Huang, He Huang, Xiaojun Jing, Hongmei Ke, Xiaoyan Li, Jianyong Li, Yuhua Liu, Qifa Lu, Peihua Mei, Heng Niu, Ting Song, Yongping Song, Yuqin Su, Liping Tu, Sanfang Wang, Jianxiang Wu, Depei Wang, Zhao Xu, Kailin Ying, Zhitao Yang, Qingming Zhang, Yajing Shi, Fengxia Zhang, Bin Zhang, Huilai Zhang, Xi Zhao, Mingfeng Zhao, Weili Zhao, Xiangyu Huang, Liang Zhu, Jun Qian, Wenbin Han, Weidong Liang, Aibin 2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma |
title | 2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma |
title_full | 2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma |
title_fullStr | 2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma |
title_full_unstemmed | 2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma |
title_short | 2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma |
title_sort | 2022 chinese expert consensus and guidelines on clinical management of toxicity in anti-cd19 chimeric antigen receptor t-cell therapy for b-cell non-hodgkin lymphoma |
topic | Consensus |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978889/ https://www.ncbi.nlm.nih.gov/pubmed/36861439 http://dx.doi.org/10.20892/j.issn.2095-3941.2022.0585 |
work_keys_str_mv | AT liping 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma AT liuyang 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma AT liangyun 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma AT bojian 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma AT gaosujun 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma AT huyongxian 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma AT huyu 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma AT huanghe 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma AT huangxiaojun 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma AT jinghongmei 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma AT kexiaoyan 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma AT lijianyong 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma AT liyuhua 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma AT liuqifa 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma AT lupeihua 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma AT meiheng 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma AT niuting 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma AT songyongping 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma AT songyuqin 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma AT suliping 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma AT tusanfang 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma AT wangjianxiang 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma AT wudepei 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma AT wangzhao 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma AT xukailin 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma AT yingzhitao 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma AT yangqingming 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma AT zhangyajing 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma AT shifengxia 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma AT zhangbin 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma AT zhanghuilai 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma AT zhangxi 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma AT zhaomingfeng 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma AT zhaoweili 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma AT zhaoxiangyu 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma AT huangliang 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma AT zhujun 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma AT qianwenbin 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma AT hanweidong 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma AT liangaibin 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma |